Typhoid Vi polysaccharide vaccine
- Generic Name
- Typhoid Vi polysaccharide vaccine
- Brand Names
- Typhim Vi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 7194H8W3KT
- Background
Typhoid Vi polysaccharide vaccine is a vaccine that is administered intramuscularly. It is an active immunization for the prevention of typhoid fever caused by S typhi and is approved for use in persons two years of age or older. The vaccine contains the purified cell surface Vi polysaccharide extracted from Salmonella enterica serovar Typhi, S typhi Ty2 strain. The bacterial culture is inactivated in the medium with the capsular polysaccharides precipated from the solution.
- Associated Conditions
- Typhoid Fever caused by S. typhi
- Associated Therapies
- -
Persistent Readiness Through Early Prediction Immunization Study
Early Phase 1
Completed
- Conditions
- Inflammatory Response
- Interventions
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Texas A&M University
- Target Recruit Count
- 249
- Registration Number
- NCT05346302
- Locations
- 🇺🇸
Texas A&M University - CTRAL, College Station, Texas, United States
Effects of Aging on Primary and Secondary Vaccine Responses
Phase 1
Completed
- Conditions
- TyphoidHealthy AdultsInfluenzaHepatitis A
- Interventions
- Biological: Typhim ViBiological: VaqtaBiological: Fluzone® quadrivalentBiological: FluadBiological: Fluzone High DoseBiological: Vivotif
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 54
- Registration Number
- NCT03312699
- Locations
- 🇺🇸
Stanford LPCH Vaccine Program, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath